HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Estee Lauder

This article was originally published in The Rose Sheet

Executive Summary

Cosmetics company will buy 1,872,000 shares of Class A common stock from Clinique Chairman and Board of Directors member Ronald Lauder for the stock's May 24 closing price of $39.25, firm announces. Additionally, Estee Lauder President & CEO William Lauder will purchase 128,000 shares of Class B common stock from Ronald Lauder at $39.25 per share, leaving William Lauder with direct ownership of 2,392,038 shares of Class B common stock and 1,168,240 shares of Class A common stock, in addition to a number of shares of Class A and Class B common stock indirectly. Transactions are slated to close May 27, at which point Ronald Lauder will directly hold 16,043,019 shares of Class B common stock and 57,553 shares of Class A common stock. He also is the beneficiary of trusts that indirectly own shares of Class A and Class B common stock underlying outstanding stock options. Lauder family will now own 88.2% of the outstanding voting power of the common stock...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel